Clinical Trials Browser

Phase 1/2 × INDUSTRY × bemarituzumab × Clear all

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05322577 2025-12-05

FORTITUDE-103

Phase 1/2 Active not recruiting

72 enrolled

Gastrointestinal

Stomach Neoplasms

Clinical Trials

FORTITUDE-301

FORTITUDE-103